1. Sah SS, Kumbhalwar A.
   Letter to the editor regarding 'Post antiretroviral treatment dynamics of blood Epstein-Barr DNA among people with HIV'.
   AIDS 2026;40:402-403.
   


2. Macias-Gonzalez F, Vermandere H, Pineirua-Menendez A, Bautista-Arredondo S, et al.
   Who is accessing PrEP in Mexico? Profiling users and identifying the unreached among high-risk MSM.
   AIDS 2026;40:397-401.
   


3. Dos Santos AP, Oliveira VHF, Willig AL, Ruderman SA, et al.
   Influence of the low-frequency extension filter on accelerometer-based activity measurements in people with HIV: a comparative analysis.
   AIDS 2026;40:394-396.
   


4. Abrescia N.
   Menopause and metabolic risk in women with HIV: beyond antiretroviral therapy.
   AIDS 2026;40:392-393.
   


5. Al-Yasiri L, Gill MJ, Krentz H, McMillan J, et al.
   Impaired CD4+ T-cell and CD4+/CD8+ ratio recovery among people with HIV on antiretroviral therapy: prevalence and risk factors.
   AIDS 2026.
   


6. Gohil J, Mackie NE, Winston A.
   The evolution of antiretroviral-associated drug-resistance mutations in an individual receiving dolutegravir/lamivudine.
   AIDS 2025;39:2147-2149.
   


7. Apollo T, Yeo YR, Mugurungi OM, Sithole N, et al.
   Case study of PEPFAR funding cuts on HIV infections and deaths: reversing hard-won gains.
   AIDS 2025;39:2143-2146.
   


8. Roberts ST, Browne EN, Moore E, Mungo J, et al.
   Longer-acting preexposure prophylaxis product and delivery preferences among transgender women in the United States: a discrete choice experiment.
   AIDS 2025;39:2140-2142.
   


9. Clark J, Caceres C.
   Centering the voices of transwomen in HIV prevention.
   AIDS 2025;39:2138-2139.
   


10. Gener AR.
    In lieu of an effective pan-viral curative treatment, does antiretroviral therapy help people clear non-HIV chronic infections?
    AIDS 2025;39:2136-2137.
    


11. Dib H, Nowak R, Niyongabo B.
    Retention challenges and cost-effective strategies for anal precancer screening in HIV-positive individuals: preventing progression to anal cancer.
    AIDS 2025;39:2133-2135.
    


12. Bishop MD, Xu L, Boyce CL, Drain PK, et al.
    HIV-1 3? polypurine tract mutations and integrase inhibitor resistance.
    AIDS 2025;39:1996-2013.
    


13. Foster C.
    Sexual and reproductive health issues facing young people with perinatal HIV infection.
    AIDS 2025;39:1985-1995.
    


14. Stevens O, Anderson RL, Sabin K, Garcia SA, et al.
    HIV prevalence in transgender women and cisgender men who have sex with men in sub-Saharan Africa 2010-2022: a meta-analysis.
    AIDS 2025.
    


15. Moyle G, Assoumou L, De Castro N, Post FA, et al.
    Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/mL and history of K103N mutation.
    AIDS 2026.
    


16. Avedissian SN, McCarthy C, Bosch RJ, Spudich S, et al.
    A novel measure of antiretroviral activity in CSF and association with HIV persistence and cognitive function.
    AIDS 2026.
    


17. Fraser H, Stone J, Zienkiewicz A, Lim AG, et al.
    Modelling the impact of underage and coerced entry into sex work on HIV transmission in Tijuana, Mexico.
    AIDS 2026.
    


18. Van Dyke RB, Sawyer GW, Williams PL, Yu W, et al.
    Longitudinal assessment of inflammatory biomarkers among youth living with perinatal HIV infection and HIV exposure.
    AIDS 2026.
    


19. Borok MZ, Fiorillo S, Manyeruke F, Makoni T, et al.
    Improved screening for pulmonary Kaposi sarcoma in a low-resource setting.
    AIDS 2026.
    


20. Caniglia EC, Zash R, Diseko M, Mabuta J, et al.
    Target trials of pre-conception switch from Nevirapine- or Efavirenz-based ART to dolutegravir-based ART on adverse birth and maternal outcomes.
    AIDS 2025.
    


21. Wang J, Zhang M, Qicheng J, Yanle Z, et al.
    Mechanism of Action of San Ren Decoction in PLWH Treatment Determined Using Network Pharmacology Combined with Experimental Validation.
    AIDS Res Hum Retroviruses 2026.
    


22. Ye L, Xu K, Luo W, Zhu M, et al.
    Identification of a Novel HIV-1 Recombinant Form (CRF01_AE/07_BC) from an Elderly Individual in Hangzhou, Eastern China.
    AIDS Res Hum Retroviruses 2026.
    


23. Ayafor V, Downes A, Lewis-Chery S, Cabral HJ, et al.
    Cancer Screening Rates, Disparities by Immigration Status and Predictors of Cancer Screening among Black Women with HIV.
    J Acquir Immune Defic Syndr 2026.
    


24. Javanbakht M, Rosen AD, Moore E, Shoptaw S, et al.
    Intersecting Vulnerabilities: The Role of Housing Instability and Methamphetamine Use on HIV Acquisition.
    J Acquir Immune Defic Syndr 2026.
    


25. Omange WR, Varco-Merth BD, Fadeyi O, Marenco A, et al.
    Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.
    J Clin Invest 2026.
    


26. Gandhi RT, Bosch RJ, Chahroudi A.
    New Insights from Perinatal HIV: A Way Forward for HIV Cure Research.
    J Infect Dis 2026.
    


27. Dabee S, Barnabas S, Versteeg B, Kullin B, et al.
    High Prevalence and Genotypic Diversity of Persistent Chlamydia Trachomatis Infections Among South African Adolescent Girls and Young Women: A Tale of Two Cities.
    J Infect Dis 2026.
    


28. McMahon EK, Lochner JS, Lynch RM, Bosque A, et al.
    Retinoids enhance NK effector function against HIV-infected CD4 T cells.
    J Virol 2026.
    


29. Gifford A, Mashau R, Mpembe R, Khanyile D, et al.
    Cryptococcal Antigenemia in South African Children Living With HIV.
    Pediatr Infect Dis J 2026.
    


30. Massa JD, Giganti MJ, Lindsey JC, Levin MJ, et al.
    Body Mass Index and Vaccine-induced Immune Responses in Children Living With HIV.
    Pediatr Infect Dis J 2026.
    

Display articles in

• Abstract format